

# News release

## **Kyowa Kirin Appoints Abdul Mullick, President, Kyowa Kirin International, to New Global Role as Vice Chief International Business Officer; Jeremy Morgan appointed President, Kyowa Kirin International**

- Abdul Mullick appointed to global role reporting to Masashi Miyamoto, President and CEO of Kyowa Kirin and working in collaboration with Toshifumi Mikayama, Executive Vice President, overseeing business operations for three regions outside Japan
- Jeremy Morgan appointed President of Kyowa Kirin International, following leadership of Rare Disease business for International region
- Both appointments support company's ongoing transformation to achieve vision to be a Japan-based Global Specialty Pharmaceutical company

**TOKYO, Japan, 8 November 2022** – Kyowa Kirin Co., Ltd., (TSE:4151, President and CEO: Masashi Miyamoto, “Kyowa Kirin”), a Japan-based Global Specialty Pharmaceutical company, today announced the appointment of Abdul Mullick, President, Kyowa Kirin International (KKI), to a new role in the global organisation, as Vice Chief International Business Officer, reporting to the Global President. Jeremy Morgan, SVP, Head of the International Rare Disease business, has been appointed President of Kyowa Kirin International.

In his new role, Abdul Mullick will work in collaboration with Toshifumi Mikayama, Executive Vice President, overseeing the North America (NA), Asia Pacific (APAC) and International/EMEA regions' business operations and the company's ongoing transformation to achieve the vision of becoming a Japan-based Global Specialty Pharmaceutical company. During his 4½ years as President of the International region, Mullick led the transformation of KKI, including establishing the company culture, building the rare disease and established medicines businesses, and ensuring a strong overall presence and impact in the market and for the patients served by the company's medicines. In his new role, Mullick will focus on achieving the company vision and One Kyowa Kirin approach across all regions outside Japan for the global organisation.

Jeremy Morgan will serve as President of KKI following Abdul Mullick's move to the global organisation. Morgan has worked at KKI for 2½ years and in that time has demonstrated a strong commitment to meeting the needs of patients and driving growth across the rare disease business. Morgan brings significant

experience to the position, having spent more than 30 years in leadership roles in various pharmaceutical companies. Morgan's appointment follows an extensive external and internal search process.

“Kyowa Kirin has a bold ambition to be a truly global organisation, bringing our Japanese heritage and the strength of our regional businesses together to live Our Philosophy and make people smile,” said Kyowa Kirin President and CEO Masashi Miyamoto. “These two appointments are another step forward on this journey, and their experience will further ensure we can deliver on our vision and bring the necessary insights and outlook to our business. I congratulate Abdul and Jeremy, and I and Board of Kyowa Kirin look forward to their continued contributions to the company and to the patients who count on us.”

Both appointments take effect 1 January 2023. Mullick will relocate to the company headquarters in Tokyo, Japan. Morgan remains based in the international region headquarters in Marlow, UK.

### **About Kyowa Kirin**

Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical company with a more than 70-year heritage, we apply cutting-edge science including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across our four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa, innovation, and integrity. You can learn more about the business of Kyowa Kirin at: <https://www.kyowakirin.com/>. Kyowa Kirin International is a subsidiary of Kyowa Kirin Co., Ltd.

### **Kyowa Kirin International**

[www.international.kyowa-kirin.com](http://www.international.kyowa-kirin.com)

Galabank Business Park  
Galashiels, TD1 1QH  
United Kingdom

### **Contacts for Kyowa Kirin International:**

#### **Media**

Stacey Minton

Email: [Stacey.Minton@kyowakirin.com](mailto:Stacey.Minton@kyowakirin.com)

### **Contacts for Kyowa Kirin Co., Ltd.:**

#### **Media**

Hiroki Nakamura

Email: [media@kyowakirin.com](mailto:media@kyowakirin.com)